European Commission - Internal Market, Industry, Entrepreneurship and SMEs

For a better experience, please enable Javascript.

Commercialisation capacity of the R&D units

Title of measure
Full title in national language:
Zwiększone urynkowienie działalności badawczo-rozwojowej
2014 to 2020
Policy objectives Plus
1.3. Research infrastructures
Presentation of the measure:

According to the diagnosis presented in the Regional Operational Programme for Podlaskie for 2014-2020, the low level of investments and innovativeness, as well as the weak connections between science and regional enterprises are key problems to be solved in the current EU financing perspective. The regional decision makers have identified it is necessary to implement actions towards the strengthening of the regional knowledge base, including the development of regional smart specialisation areas and connecting the 'traditional' economic profile of the region with modern technologies. The measure 1.1. "Commercialisation capacity of the R&D units " implemented in the form of a grant scheme in the framework of the Regional Operational Programme for Podlaskie for 2014-2020 was planned as one of the tools for thge improvement of the abovementioned challenge. The objective of the measure is to ensure the development of the R&D infrastructure in regional scientific units, enabling the future implementation of the RIS3-related projects for companies, and improvement of the effectiveness of efforts in R&D commercialisation.  
In the framework of this measure, the projects eligible for funding have to be focused on the development of R&D infrastructure of research units, which is necessary for conducting of projects with the participation of regional enterprises. One of the preconditions for funding is the presentation of a reliable business plan outlining the future possibilities of the use of the supported infrastructure by the regional companies.
The total budget of the measure amounts to €30m, and the eligible beneficiaries are research units, universities, as well as research consortia.

Budget, source and type of funding
National public funds
Regional public funds
EU Structural Funds 30000000 30000000 30000000 30000000 30000000 30000000 30000000
Private funds 3300000330000033000003300000330000033000003300000
Form of funding provided
Policy learning
To what extent the measure can be considered as a success and worthy of policy learning?:
It is too early to judge the success of the measure (e.g results of first call for proposals still not known).
Evidence of outcomes based on evaluation and other evidence:

The only one project is implemented in the Measure 1.1. Its implementation could not start due to difficulties in finding an economic partner. It should be assumed that the planned target values of all indicators will be achieved, which results from the fact that under Measure 1.1 only one project is selected. In this activity, the planned values of indicators are equal to the target values from the Programme. This should not be surprising as the Medical University of Bialystok was the only scientific unit whose project was included in the Annex No. 2 to the Territorial Contract for the Podlaskie Voivodeship.

What are the most important “Do’s and Don’ts” that regional stakeholders should be aware of when launching a similar measure?:

The experience gained during the implementation of a similar measure in the previous programming period illustrates well that projects supported in the framework of this type of measures should before the funding prove the appropriateness of the supported R&D infrastructure to the needs of regional entrepreneurs. 

Would you recommend this measure as an example of regional good practice to policy-makers from other regions ?:
Organisation(s) responsible
Evaluation report(s)